Biofrontera reports Q3 2026 results after Ameluz sBCC approval and ITC lamp ruling
FDA cleared Ameluz for superficial basal cell carcinoma and customs regulators allowed Biofrontera's redesigned XL-C lamp back into the US, as quarterly revenue rose 30%.
SEC filing